How to Buy Panacea Biotec Ltd Shares?
You can easily buy the stocks/shares of Panacea Biotec Ltd (PANACEABIO) on Tickertape or through broker platform by opening a Demat & Trading account onlineWhat is the Share Price of Panacea Biotec Ltd?
The stock prices are volatile and keep changing through the day depending upon various factors and market conditions. The Share price of PANACEABIO as on 15th May 2025 is ₹566.04What is the return on Panacea Biotec Ltd share?
The past returns of Panacea Biotec Ltd (PANACEABIO) share are- Past 1 week: N/A
- Past 1 month: N/A
- Past 3 months: -7.30
- Past 6 months: -3.27
- Past 1 year: 211.37
- Past 3 years: 222.87
- Past 5 years: 101.68
What is the Dividend yield % on Panacea Biotec Ltd share?
The current dividend yield of Panacea Biotec Ltd (PANACEABIO) is N/AWhat is the Market Cap of Panacea Biotec Ltd?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Panacea Biotec Ltd (PANACEABIO) is ₹2626.13Cr as of 15th May 2025What is the 52 Week High and Low of Panacea Biotec Ltd?
The 52-week high and low of Panacea Biotec Ltd (PANACEABIO) is ₹581.90 and ₹130.What is the PE and PB ratio of Panacea Biotec Ltd?
The P/E (price-to-earnings) and P/B (price-to-book) ratios of Panacea Biotec Ltd are -313.75 and 3.11 respectively.Which sector does Panacea Biotec Ltd belong to?
Panacea Biotec Ltd (PANACEABIO) belongs to the Health Care sector & Biotechnology sub-sector.What are the peers or stocks similar to Panacea Biotec Ltd?
The peers or stocks similar to Panacea Biotec Ltd are: and many others.Can't decide whether or not to buy Panacea Biotec Ltd?
Worry no more! Login to Tickertape and check out Panacea Biotec Ltd (PANACEABIO) scorecard & all the relevant insights today5. Test Stocks FAQ What is the 52 Week High and Low of Panacea Biotec Ltd?
The 52-week high and low of Panacea Biotec Ltd (PANACEABIO) is ₹581.90 and ₹130.1. Test Stocks FAQ for Panacea Biotec Ltd Shares?
You can easily buy the stocks/shares of Panacea Biotec Ltd (PANACEABIO) on Tickertape or through broker platform by opening a Google & Trading account online3. Test Stocks FAQ What is the Share Price of Panacea Biotec Ltd?
The stock prices are volatile and keep changing through the day depending upon various factors and market conditions. The Share price of PANACEABIO as on 15th May 2025 is ₹566.04
Panacea Biotec Ltd
PANACEABIO Share Price
566.040.03% (-0.16)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
PANACEABIO Stock Scorecard
Performance
AvgPrice return has been average, nothing exciting
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
AvgAverage profitability - not good, not bad
Entry point
AvgThe stock is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
PANACEABIO Performance & Key Metrics
PANACEABIO Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| -310.78 | 3.11 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 35.65 | 6.54 | 0.85% |
PANACEABIO Analyst Ratings & Forecast
—
Analyst Ratings data is currently unavailable for this stockPrice Upside
Earnings Growth
Rev. Growth
PANACEABIO Company Profile
Panacea Biotec Limited is a health management company. The Company's principal business activity is the manufacture of allopathic pharmaceuticals preparations.
BIOCON
PE Ratio
40.44
40.44
1Y Return
2.92%
2.92%
Buy Reco %
63.64
63.64
ONESOURCE
PE Ratio
-1,398.96
-1,398.96
1Y Return
13.89%
13.89%
Buy Reco %
—
—
SAILIFE
PE Ratio
90.49
90.49
1Y Return
8.95%
8.95%
Buy Reco %
—
—
ACUTAAS
PE Ratio
57.13
57.13
1Y Return
64.77%
64.77%
Buy Reco %
100.00
100.00
HESTERBIO
PE Ratio
55.84
55.84
1Y Return
32.19%
32.19%
Buy Reco %
0.00
0.00
PANACEABIO Sentiment Analysis
PANACEABIO Sentiment Analysis
New
Crisp summary & key insights to decode earnings calls instantly
PANACEABIO Stock Summary · January 2025
Company is navigating a complex landscape characterized by declining market share in deposits, challenges in meeting Priority Sector Lending (PSL) obligations, and fluctuations in current account flows. Despite these hurdles, the bank is focusing on enhancing customer engagement and service delivery to drive deposit growth, with recent monthly inflows showing a positive trend. The management emphasizes a strategic approach to maintaining profitability over aggressive expansion, particularly in light of competitive pressures and a tight liquidity environment. Efforts to improve operational efficiencies through digitization and a commitment to stable cost management are underway, alongside a proactive strategy to reduce borrowings and strengthen the balance sheet. Overall, while facing short-term challenges, the bank remains optimistic about future performance and is committed to achieving sustainable growth through strategic investments and improved customer outreach.
PANACEABIO Stock Growth Drivers
PANACEABIO Stock Growth Drivers
2Focus on Sustainable Growth
Company is prioritizing profitable growth over mere expansion, emphasizing a strategy that encourages ground-level teams
Stable Financial Metrics
The company has maintained a return on assets (ROA) of 1.9% post-merger, showcasing stability in
PANACEABIO Stock Challenges
PANACEABIO Stock Challenges
3Deposit Growth Shortfalls
The company has experienced deposit growth that has not met expectations, attributed to seasonal trends
Loan Growth Concerns
There is uncertainty regarding the company's loan deposit ratio (LDR) and its implications for loan
PANACEABIO Forecast
What are forecasts?
What are forecasts?
Forecasting uses historical data as inputs to make informed predictive estimates determining the direction of future trends. Price, revenue & earnings forecasts represent where the stock level, business prospects and profits are potentially expected to be at the end of the forecast period
PANACEABIO Forecasts
Forecast data is currently unavailable
Forecast data is currently unavailable
Price
Price Upside
Revenue
Revenue Growth
Earnings
Earnings Per Share
PANACEABIO
PANACEABIO
Income
Balance Sheet
Cash Flow
Annual Normal View
PANACEABIO Income Statement
PANACEABIO Income Statement
Annual Normal View
| Financial Year | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 598.59 | 600.78 | 795.34 | 574.08 | 634.86 | 2,348.41 | 614.27 | 621.00 | 615.74 | 615.74 | ||||||||||
Raw Materials | 158.42 | 197.98 | 135.06 | 190.01 | 199.02 | 311.17 | 218.29 | 212.27 | 585.00 | 585.00 | ||||||||||
| Power & Fuel Cost | 30.55 | 33.52 | 34.55 | 29.74 | 30.94 | 37.82 | 31.95 | 35.95 | ||||||||||||
| Employee Cost | 148.12 | 151.59 | 147.08 | 142.32 | 156.17 | 182.97 | 126.48 | 149.57 | ||||||||||||
| Selling & Administrative Expenses | 86.07 | 68.92 | 94.77 | 83.69 | 75.20 | 102.87 | 70.56 | 70.78 | ||||||||||||
| Operating & Other expenses | 73.74 | 57.06 | 179.67 | 88.77 | 88.30 | 39.60 | 110.63 | 110.66 | ||||||||||||
EBITDA | 101.69 | 91.71 | 204.21 | 39.55 | 85.23 | 1,673.98 | 56.36 | 41.77 | 30.74 | 30.74 | ||||||||||
| Depreciation/Amortization | 67.95 | 57.28 | 54.00 | 43.22 | 45.59 | 43.78 | 39.12 | 36.71 | 34.81 | 34.81 | ||||||||||
| PBIT | 33.74 | 34.43 | 150.21 | -3.67 | 39.64 | 1,630.20 | 17.24 | 5.06 | -4.07 | -4.07 | ||||||||||
| Interest & Other Items | 100.93 | 100.58 | 104.83 | 173.98 | 185.34 | 180.84 | 4.44 | 3.58 | 3.88 | 3.88 | ||||||||||
| PBT | -67.19 | -66.15 | 45.38 | -177.65 | -145.70 | 1,449.36 | 12.80 | 1.48 | -7.95 | -7.95 | ||||||||||
| Taxes & Other Items | -12.70 | 7.84 | 7.65 | 16.61 | 1.99 | 371.04 | 46.04 | 2.65 | 0.42 | 0.50 | ||||||||||
| Net Income | -54.49 | -73.99 | 37.73 | -194.26 | -147.69 | 1,078.32 | -33.24 | -1.17 | -8.37 | -8.45 | ||||||||||
| EPS | -8.16 | -11.08 | 5.65 | -29.10 | -23.07 | 176.05 | -5.43 | -0.19 | -1.37 | -1.38 | ||||||||||
| DPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||||||
| Payout ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
PANACEABIO Company Updates
PANACEABIO Stock Peers
What are peers and why compare against them?
What are peers and why compare against them?
A stock's peers are companies which have similar business interests, operations and belong to the same industry sector. Comparing various metrics against peers can give valuable insights on whether the company's stock is over/under-valued and the company's growth outlook vs the industry as a whole
PANACEABIO Past Performance & Peer Comparison
PANACEABIO Past Performance & Peer Comparison
Comparing 3 stocks from
Health CareBiotechnology
Compare valuation-basic on Screener
Health CareBiotechnology
Valuation
Technical
Forecast
Compare valuation-basic on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Panacea Biotec Ltd | -313.75 | 3.11 | — |
| Biocon Ltd | 40.44 | 1.62 | 0.37% |
| Onesource Specialty Pharma Ltd | -1,398.96 | 63.49 | — |
| Sai Life Sciences Ltd | 90.49 | 15.79 | — |
PANACEABIO Stock Price Comparison
Compare PANACEABIO with any stock or ETFCompare PANACEABIO with any stock or ETF
PANACEABIO
PANACEABIO Holdings
PANACEABIO Shareholdings
What are shareholdings?
What are shareholdings?
Apart from retail investors, a company’s shares are held by promoters, foreign & domestic institutions (large investors) and mutual funds. Promoters are the ship captains and control the company’s direction. Along with institutional and mutual fund holdings, a change in their holdings can indicate performance outlook for the stock
PANACEABIO Promoter Holdings Trend
PANACEABIO Promoter Holdings Trend
Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
PANACEABIO Institutional Holdings Trend
PANACEABIO Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
PANACEABIO Shareholding Pattern
PANACEABIO Shareholding Pattern
PANACEABIO Shareholding History
PANACEABIO Shareholding History
Foreign Institutions
smallcases containing PANACEABIO stock
smallcases containing PANACEABIO stock
Looks like this stock is not in any smallcase yet.
PANACEABIO Events
PANACEABIO Events
PANACEABIO Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
PANACEABIO has not given any dividends in last 5 years
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
What are dividends?
What are dividends?
Dividends are a portion of earnings that a company distributes to all its shareholders every year. Dividend return is one of the most important things to be considered while investing for long term. It’s the additional return on top of what investors earn through price appreciation
PANACEABIO Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
PANACEABIO has not given any dividends in last 5 years
PANACEABIO Upcoming Dividends
PANACEABIO Upcoming Dividends
No upcoming dividends are available
PANACEABIO Past Dividends
PANACEABIO Past Dividends
Cash Dividend
Ex DateEx DateSep 19, 2011
Final
Final | Div/Share: ₹0.75
Dividend/Share
₹0.75
Ex DateEx Date
Sep 19, 2011
Cash Dividend
Ex DateEx DateSep 16, 2010
Final
Final | Div/Share: ₹0.25
Dividend/Share
₹0.25
Ex DateEx Date
Sep 16, 2010
PANACEABIO Stock News & Opinions
PANACEABIO Stock News & Opinions
Articles & Videos
Corporate
Panacea Biotec announces inclusion of EmulsiPan into prestigious CEPI Adjuvant Library
Panacea Biotec announced the listing of EmulsiPan in the CEPI (Coalition for Epidemic Preparedness Innovations) Library of adjuvants to support the scientific community in advancing vaccine and biotherapeutic development. EmulsiPan has been recognized for its potential in enhancing the efficacy and dose-sparing effects. EmulsiPan is an oil-in-water emulsion adjuvant and is produced by nano-emulsification of squalene along with surfactants and buffers. Squalene is a naturally occurring biodegradable and biocompatible triterpene hydrocarbon found in many plants as well as in humans. EmulsiPan is a ready-to-use sterile emulsion, supplied in a 10 mL USP Type I glass vial for research purposes. It is designed for storage at 2-8'C and maintains stability for over 2-years under recommended conditions. On the occasion, the Chairman and Managing Director, Panacea Biotec, Dr. Rajesh Jain said, 'It is with great pride that we announce the availability of EmulsiPan, a ready-to-use dose sparing adjuvant designed to enhance vaccine efficacy and support global public health initiatives. Such investments showcase our commitment to research and development investments that provide us the edge to not just meet ongoing challenges but also create a future-ready company that is prepared for every possibility and opportunity.' Powered by Capital Market - Live
2 weeks agoCapital Market - Live
Earnings
Panacea Biotec reports consolidated net loss of Rs 1.89 crore in the March 2025 quarter
Net Loss of Panacea Biotec reported to Rs 1.89 crore in the quarter ended March 2025 as against net loss of Rs 1.99 crore during the previous quarter ended March 2024. Sales declined 2.88% to Rs 132.53 crore in the quarter ended March 2025 as against Rs 136.46 crore during the previous quarter ended March 2024. For the full year,net loss reported to Rs 8.37 crore in the year ended March 2025 as against net loss of Rs 1.17 crore during the previous year ended March 2024. Sales declined 0.01% to Rs 559.09 crore in the year ended March 2025 as against Rs 559.17 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales132.53136.46 -3 559.09559.17 0 OPM %-20.28-4.43 --4.63-3.59 - PBDT-19.333.95 PL -9.132.16 PL PBT-27.75-4.86 -471 -43.94-34.55 -27 NP-1.89-1.99 5 -8.37-1.17 -615 Powered by Capital Market - Live
3 weeks agoCapital Market - Live
Corporate
Panacea Biotec declare Quarterly Result
Panacea Biotec will hold a meeting of the Board of Directors of the Company on 30 May 2025.Powered by Capital Market - Live
4 weeks agoCapital Market - Live
Earnings
Panacea Biotec reports consolidated net profit of Rs 4.52 crore in the December 2024 quarter
Net profit of Panacea Biotec reported to Rs 4.52 crore in the quarter ended December 2024 as against net loss of Rs 2.28 crore during the previous quarter ended December 2023. Sales rose 8.63% to Rs 163.49 crore in the quarter ended December 2024 as against Rs 150.50 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales163.49150.50 9 OPM %4.87-0.10 - PBDT10.594.68 126 PBT1.61-4.43 LP NP4.52-2.28 LP Powered by Capital Market - Live
4 months agoCapital Market - Live
Corporate
Panacea Biotec to announce Quarterly Result
Panacea Biotec will hold a meeting of the Board of Directors of the Company on 14 February 2025.Powered by Capital Market - Live
4 months agoCapital Market - Live
Corporate
Panacea Biotec Pharma launches 'NikoMom' brand of baby diapers and wipes
Panacea Biotec announced that the company's wholly owned subsidiary, Panacea Biotec Pharma (PBPL) has launched baby diapers and wipes under the brand name 'NikoMom'. Powered by Capital Market - Live
5 months agoCapital Market - Live
Corporate
Panacea Biotec announces investment in Panacea Biotec Inc.
Panacea Biotec announced that the company's material subsidiary, Panacea Biotec Pharma (PBCL) has made further investment of US$ 9,25,000 (~Rs.7.92 crore) in its wholly owned subsidiary, Panacea Biotec Inc. (PB Inc.) subscription for 9,25,00,000 shares of common stock of PB Inc. at a price of US$ 0.01 per share. Panacea Biotec Inc. being a step-down subsidiary of the company. The investment made by PBPL in WOS is to facilitate the capex and working capital requirements of PB Inc. and is in furtherance of its business. The business of the WOS is in line with the business activities of the Company and PBPL. Powered by Capital Market - Live
5 months agoCapital Market - Live
Spotlight
Panacea Biotec hits the roof on bagging order worth Rs 127-cr from UNICEF
The contract is worth $14.95 million (approximately Rs 127 crore). The said order will be executed by calendar year 2025, subject to signing of requisite amendment to the long term arrangement. The project entails supply of bOPV to UNICEF for its requirements in countries in Africa and Asia region as per the orders as may be received from time to time. Panacea Biotec is engaged in the business of research, development, manufacture, and marketing of branded pharmaceutical formulations in India and international markets. The company reported consolidated net loss of Rs 8.29 crore in Q2 FY24 as compared with net profit of Rs 15.70 crore reported in Q2 FY23. Net sales jumped 36.1% YoY to Rs 143.02 crore in Q2 FY24.Powered by Capital Market - Live
5 months agoCapital Market - Live
Corporate
Panacea Biotec wins order of Rs 127 cr from UNICEF
Panacea Biotec has received a Letter of Award from UNICEF for supply of 115 million doses of its bivalent oral polio vaccine (bOPV) worth ~US$ 14.95 million (~Rs.127 crore) in CY2025.Powered by Capital Market - Live
5 months agoCapital Market - Live
Earnings
Panacea Biotec reports consolidated net profit of Rs 4.71 crore in the September 2024 quarter
Net profit of Panacea Biotec reported to Rs 4.71 crore in the quarter ended September 2024 as against net loss of Rs 8.29 crore during the previous quarter ended September 2023. Sales rose 3.03% to Rs 147.35 crore in the quarter ended September 2024 as against Rs 143.02 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales147.35143.02 3 OPM %4.75-2.49 - PBDT10.67-1.24 LP PBT1.99-10.55 LP NP4.71-8.29 LP Powered by Capital Market - Live
7 months agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of -4.83%, vs industry avg of 19.23%
Over the last 5 years, market share decreased from 10.06% to 3.24%